Clinical relevance of the use of Dentoxol® for oral mucositis induced by radiotherapy: A phase II clinical trial

Table 3 Measures of clinical significance for the effect of Dentoxol^® on severe oral mucositis

Week	AR		RR (95%CI)	ARR	RRR	NNT	OR (95%CI)
	Dentoxol (%)	Control (%)	Dentoxol®	Dentoxol® (%)	Dentoxol® (%)	Dentoxol®	Dentoxol®
1	5.77	2	2.88 (0.31-26.82)	-4	-188	-27	3 (0.30-29.85)
2	0	4.55	-	5	100	22	-
3	4.08	23.08	0.18 (0.04-0.77)	19	82.31	5	0.14 (0.03-0.70)
4	8.7	29.27	0.3 (0.1-0.85)	21	70.29	5	0.23 (0.07-0.78)
5	26.67	47.22	0.56 (0.31-1.02)	21	43.53	5	0.41 (0.16-1.03)
6	35.56	53.13	0.67 (0.4-1.12)	18	33.07	6	0.49 (0.29-1.23)
7	42.11	56	0.75 (0.45-1.25)	14	24.81	7	0.57 (0.21-1.58)
8	35.29	55.56	0.64 (0.27-1.52)	20	36.47	5	0.44 (0.08-2.27)

ARR: Absolute risk reduction; RR: Relative risk; RRR: Relative risk reduction; NNT: Number necessary to treat; OR: Odds ratio.